14.76
                                            Precedente Chiudi:
              $15.04
            Aprire:
              $14.85
            Volume 24 ore:
                31,191
            Relative Volume:
              0.62
            Capitalizzazione di mercato:
                $2.57B
            Reddito:
              $603.63M
            Utile/perdita netta:
              $468.71M
            Rapporto P/E:
              5.5034
            EPS:
                2.682
            Flusso di cassa netto:
                $-59.92M
            1 W Prestazione:
              -2.51%
            1M Prestazione:
              -7.05%
            6M Prestazione:
                -6.23%
            1 anno Prestazione:
              -28.18%
            Hutchmed China Limited Adr Stock (HCM) Company Profile
Confronta HCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS | 
|---|---|---|---|---|---|---|
|   
                          
                                HCM
                            
                             Hutchmed China Limited Adr | 14.76 | 2.58B | 603.63M | 468.71M | -59.92M | 2.682 | 
|   
                          
                                ZTS
                            
                             Zoetis Inc | 145.94 | 64.88B | 9.39B | 2.62B | 2.22B | 5.8121 | 
|   
                          
                                TAK
                            
                             Takeda Pharmaceutical Co Adr | 14.01 | 44.40B | 29.96B | 957.25M | 4.77B | 0.2956 | 
|   
                          
                                HLN
                            
                             Haleon Plc Adr | 9.25 | 41.72B | 14.26B | 1.98B | 2.47B | 0.4327 | 
|   
                          
                                TEVA
                            
                             Teva Pharmaceutical Industries Ltd Adr | 18.95 | 21.82B | 16.70B | -157.13M | 1.19B | -0.1446 | 
|   
                          
                                UTHR
                            
                             United Therapeutics Corp | 418.58 | 19.28B | 3.08B | 1.24B | 1.07B | 25.61 | 
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione | 
|---|---|---|---|
| 2025-09-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight | 
| 2025-05-13 | Downgrade | HSBC Securities | Buy → Hold | 
| 2023-11-24 | Aggiornamento | Deutsche Bank | Hold → Buy | 
| 2022-05-04 | Downgrade | Deutsche Bank | Buy → Hold | 
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral | 
| 2021-08-03 | Iniziato | Jefferies | Buy | 
| 2020-10-02 | Iniziato | Deutsche Bank | Buy | 
| 2020-03-13 | Iniziato | Cantor Fitzgerald | Overweight | 
| 2020-02-20 | Iniziato | Goldman | Buy | 
| 2019-11-19 | Iniziato | CLSA | Buy | 
| 2019-10-23 | Reiterato | BofA/Merrill | Buy | 
| 2019-07-05 | Iniziato | Macquarie | Outperform | 
                    Mostra tutto
                     
                  
                Hutchmed China Limited Adr Borsa (HCM) Ultime notizie
Vanguard Personalized Indexing Management LLC Grows Holdings in Sandstorm Gold Ltd $SAND - Defense World
Market news - investments.halifax.co.uk
RCSHutchmed China LtdHUTCHMED Presents Data at AACR NCI EORTC - TradingView
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
HUTCHMED Highlights HMPL-A251 Data Presented at the - GlobeNewswire
Allianz Asset Management GmbH Sells 80,000 Shares of HUTCHMED (China) Limited Sponsored ADR $HCM - MarketBeat
Will Can Fite Biopharma Ltd Sponsored ADR stock benefit from mergersQuarterly Risk Review & Risk Controlled Stock Alerts - nchmf.gov.vn
Pfizer: CN Biopharma Sector Shows Astonishing Growth; US Drug Industry Must Collaborate with CN - AASTOCKS.com
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress - The Manila Times
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Why HUTCHMED (China) Limited (Common Stock) (H7T1) stock is favored by hedge fundsTrade Exit Report & Technical Entry and Exit Alerts - newser.com
Will HUTCHMED (China) Limited (Common Stock) (H7T1) stock deliver stable dividendsPortfolio Update Report & Verified Chart Pattern Signals - newser.com
BOCOMI: Trump's Additional Tariffs on Imported Innovative Drugs May Have Limited Actual Impact on CN Pharmas - AASTOCKS.com
HUTCHMED (NASDAQ:HCM) Shares Gap DownTime to Sell? - MarketBeat
M Stanley: Increased Recognition Pushes Biotech Stocks to Outpace Mkt - AASTOCKS.com
Best Momentum Stock to Buy for August 19th - MSN
National Research Corporation $NRC Shares Sold by Goldman Sachs Group Inc. - Defense World
HUTCHMED (China) Limited Sponsored ADR $HCM Stock Position Raised by Goldman Sachs Group Inc. - Defense World
HUTCHMED (NASDAQ:HCM) Shares Gap UpHere's What Happened - MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap Up – Should You Buy? - Defense World
Price action breakdown for HUTCHMED (China) Limited Depositary Receipt2025 Dividend Review & Risk Managed Investment Strategies - newser.com
Top Blockchain Stocks To Follow Now – September 12th - Defense World
HSBC Research Positive on LT Growth of CN Biotech, Favors INNOVENT BIO/ HANSOH PHARMA - AASTOCKS.com
G Sachs Gives ST Risk Analysis for 3 Types of Firms as US Reportedly Planning to Tighten Scrutiny on CN Innovative Drugs Could Pose 'Headline Risks' for CN Pharmas - AASTOCKS.com
CN SASAC Advocates to Accelerate Development of Central SOEs in the Biopharmaceutical Industry, Build National Team in Such Field - AASTOCKS.com
Intraday pattern recognizer results for HUTCHMED (China) Limited Depositary Receipt2025 Biggest Moves & Trade Opportunity Analysis Reports - Newser
Combining machine learning predictions for HUTCHMED (China) Limited Depositary ReceiptQuarterly Market Review & Verified Entry Point Signals - Newser
How moving averages guide HUTCHMED (China) Limited Depositary Receipt trading2025 Retail Activity & Stepwise Trade Signal Implementation - Newser
HUTCHMED Announces Appointment of Acting Chief Executive Officer - GlobeNewswire Inc.
Solventum Corporation $SOLV Shares Sold by Russell Investments Group Ltd. - Defense World
HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China - GlobeNewswire
Best Momentum Stock To Buy For August 19th - Barchart.com
How to build a custom watchlist for HUTCHMED (China) Limited Depositary Receipt2025 Price Action Summary & Verified Momentum Stock Ideas - Newser
BOCOMI Lowers HUTCHMED's TP to HKD37.6; Rating Kept Buy - AASTOCKS.com
Will HUTCHMED (China) Limited Depositary Receipt bounce back from current supportFree Oversold Recovery Opportunity Stocks - Newser
Analysts Have Conflicting Sentiments on These Healthcare Companies: Zymeworks (ZYME), HUTCHMED (HCM) and Zai Lab (ZLAB) - The Globe and Mail
Trend analysis for HUTCHMED (China) Limited Depositary Receipt this weekStock Holding Strategy Long-Term Summary Sheet - Newser
Carvana Co. (NYSE:CVNA) Major Shareholder Sells $35,236,000.00 in Stock - Defense World
Crossmark Global Holdings Inc. Sells 414 Shares of Morningstar, Inc. (NASDAQ:MORN) - Defense World
6,121 Shares in John Hancock Multifactor Large Cap ETF (NYSEARCA:JHML) Bought by Crossmark Global Holdings Inc. - Defense World
Concurrent Investment Advisors LLC Acquires New Holdings in ADMA Biologics Inc (NASDAQ:ADMA) - Defense World
Crossmark Global Holdings Inc. Has $356,000 Holdings in Nordson Corporation (NASDAQ:NDSN) - Defense World
Buenaventura Mining (NYSE:BVN) vs. Hochschild Mining (OTCMKTS:HCHDF) Head-To-Head Review - Defense World
Coinbase Global, Inc. (NASDAQ:COIN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
HUTCHMED Gains China Approval for Innovative Lung Cancer Treatment - TipRanks
HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy - GlobeNewswire
HUTCHMED (NASDAQ:HCM) Rating Increased to Strong-Buy at Wall Street Zen - Defense World
Rhumbline Advisers Has $50,000 Position in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) - Defense World
How Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52% - Nasdaq
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Bought by Bank of America Corp DE - Defense World
Public Employees Retirement System of Ohio Has $39,000 Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Hutchmed China Limited Adr Azioni (HCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
        Apri su Yahoo
        |
        Apri su Google
            |
            Aperto in Finviz
        |
        Apri in MarketWatch
            |
            Aperto a EDGAR    
        |
        Aperto su Reuters
    
    
                Capitalizzazione:
                 
                  | 
                Volume (24 ore):
                 
            
         
                     
                             Scarica l'app Stockscreener
                    Scarica l'app Stockscreener